Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Acute Respiratory Distress Syndrome (ARDS)Multiple Organ Failure
Interventions
DRUG

conventional ECMO with intravenous steroid

refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable

DRUG

solumedrol

Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 \> FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.

Trial Locations (1)

10002

Department of Surgery, National Taiwan University Hospital, 7, Chung-Shan S. Rd, Taipei 10002, Taiwan.

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER

NCT01423864 - Intrapleural Methylprednisolone Injection for Multiple Organ Failure With Acute Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter